The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus

Therapeutic Drug Monitoring

Volumn 34, Issue 1, 2012, Pages 38-45

  Akhlaghi, Fatemeh ^a   Dostalek, Miroslav ^a   Falck, Pål ^b   Mendonza, Anisha E ^a   Amundsen, Rune ^b   Gohh, Reginald Y ^c   Åsberg, Anders ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c BROWN UNIVERSITY   (United States)

Author keywords

biotransformation; cyclosporine; cytochrome P450 3A4; diabetes mellitus; ketoconazole; pharmacokinetics

Indexed keywords

AM1; AM19; AM1C; AM1C9; AM4N; AM9; CYCLOSPORIN A; CYTOCHROME P450 3A5; DRUG METABOLITE; KETOCONAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; AGED; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN;

EID: 84856115696     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318241ac71     Document Type: Article

References (31)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27: 1047-1053. (Pubitemid 38579764)
2. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3: 178-185. (Pubitemid 36323115)
3. Marques MP, Coelho EB, Dos Santos NA, et al. Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol. 2002;58:607-614. (Pubitemid 35478187)
4. Moises EC, Duarte Lde B, Cavalli Rde C, et al. Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. Eur J Clin Pharmacol. 2008;64:1189-1196.
5. Dostalek M, Court MH, Yan B, et al. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol. 2011;163:937-947.
6. Fahr A. Cyclosporine clinical pharmacokinetics. Clin Pharmacokinet. 1993;24:472-495.
7. Christians U, Strohmeyer S, Kownatzki R, et al. Investigations on the metabolic pathways of cyclosporine: II. Elucidation of the metabolic pathways in vitro by human liver microsomes. Xenobiotica. 1991;21: 1199-1210.
8. Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc. 1986;18:25-34. (Pubitemid 17223775)
9. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2001;2:51-64. (Pubitemid 32633651)
10. Mendonza AE, Gohh RY, Akhlaghi F. Blood and plasma pharmacokinetics of cyclosporine in diabetic kidney transplant recipients. Clin Pharmacokinet. 2008;47:733-742.
11. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003;43:555-564. (Pubitemid 36613114)
12. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995;333: 628-633.
13. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48: 1668-1671.
14. Falck P, Guldseth H, Asberg A, et al. Determination of cyclosporine A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:345-352. (Pubitemid 46830123)
15. von Moltke LL, Granda BW, Grassi JM, et al. Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab Dispos. 2004; 32:800-804. (Pubitemid 38955608)
16. Huang Q, Wang GJ, Sun JG, et al. Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/ electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:1009-1018. (Pubitemid 46426822)
17. Dostalek M, Macwan JS, Chitnis SD, et al. Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1'-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:1629-1633.
18. de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimustreated renal allograft recipients. Clin Pharmacol Ther. 2011;90: 414-422.
19. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II). Clin Pharmacokinet. 1990;19:218-229. (Pubitemid 20281451)
20. Akhlaghi F, Trull AK. Distribution of cyclosporine in organ transplant recipients. Clin Pharmacokinet. 2002;41:615-637.
21. Lampen A, Christians U, Bader A, et al. Drug interactions and interindividual variability of cyclosporine metabolism in the small intestine. Pharmacology. 1996;52:159-168. (Pubitemid 26076283)
22. Dai Y, Iwanaga K, Lin YS, et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol. 2004;68:1889-1902. (Pubitemid 39278511)
23. Christians U, Strohmeyer S, Kownatzki R, et al. Investigations on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile-isolation of 12 new cyclosporine metabolites. Xenobiotica. 1991;21:1185-1198.
24. Maurer G, Loosli HR, Schreier E, et al. Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos. 1984;12:120-126. (Pubitemid 14189051)
25. Hashem H, Venkataramanan R, Burckart GJ, et al. Identification of the aldehydic metabolites. Transplant Proc. 1988;20:176-178.
26. Wallemacq PE, Lhoest G, Dumont P. Isolation, purification and structure elucidation of cyclosporine A metabolites in rabbit and man. Biomed Environ Mass Spectrom. 1989;18:48-56. (Pubitemid 19039051)
27. Christians U, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem. 1995;28:547-559.
28. First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. Transplantation. 1993;55:1000-1004. (Pubitemid 23150721)
29. Yasuda K, Lan LB, Sanglard D, et al. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002;303:323-332.
30. Soldin SJ, Steele BW, Witte DL, et al. Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. Arch Pathol Lab Med. 2003;127:19-22. (Pubitemid 36236574)
31. Morris RG. Cyclosporine assays, metabolite cross-reactivity, and pharmacokinetic monitoring. Ther Drug Monit. 2000;22:160-162. (Pubitemid 30196818)